Immunotherapy for the Treatment of Melanoma and Lung Cancer
Immunotherapy has improved outcomes for patients with cancer, despite several drawbacks. This review provides an overview of how to manage patients undergoing therapy with these drugs.
Melanoma
Tecentriq Plus Cotellic and Zelboraf Approved for Advanced Melanoma
The approval was based on data from the multicenter, double-blind, placebo-controlled phase 3 IMspire150 study.
Pembrolizumab Use Supported in Advanced Melanoma
Use supported regardless of BRAF V600E/K mutation status, receipt of prior BRAFi with/without MEKi.
Reduced-Frequency Follow-up of Patients With Melanoma Effective and Accepted
Nurse-led posttreatment care at a lower frequency did not negatively affect care or patient satisfaction with their care.
UV, Sex, and Age Contribute to Melanoma Tumor Evolution
New tools examine the rate of mutation accumulation in melanoma, and the effect of sex and age on tumor development.
Vitamin D May Cut Colitis Risk for Immune Checkpoint Inhibitors
Odds of developing ICI colitis significantly reduced with vitamin D use in patients with melanoma.
Study Investigates Association Between Height and Risk of Invasive Melanoma
This study used data from the Nurses’ Health Study (NHS) and NHS2 to explore the association between height, number of nevi, and risk of invasive melanoma.
Melanoma Risk From Biologic Therapy Remains Uncertain
Systematic literature review and meta-analysis reveal link to increased risk cannot be ruled out.
Exposure to Antibiotics Associated With Survival Detriment in Patients With Advanced Melanoma Treated With ICIs
Previous studies have shown an association between gut microbiome diversity and response to immune checkpoint inhibitor therapy.
Minority of Melanomas With Complete Response to Anti–PD-1 Relapsed After Drug Cessation
More research is needed to define criteria for stopping therapy.
-
Loading...
-
Loading...
Next post in Melanoma
